Skip to main content

Recent advances in breast cancer treatment

This special series showcases the advances in our understanding that has driven the substantial progress made in the targeted therapy of breast cancer, bringing together the translational research behind these new approaches as well as reviewing treatments with early evidence of efficacy that are still in clinical development.

Jenny Chang

  1. Urokinase plasminogen activator (uPA) is an extracellular matrix-degrading protease involved in cancer invasion and metastasis, interacting with plasminogen activator inhibitor-1 (PAI-1), which was originally ...

    Authors: Michael J Duffy, Patricia M McGowan, Nadia Harbeck, Christoph Thomssen and Manfred Schmitt
    Citation: Breast Cancer Research 2014 16:428
  2. The estrogen receptor and human epidermal growth factor receptor (HER) signaling pathways are the dominant drivers of cell proliferation and survival in the majority of human breast cancers. Not surprisingly, ...

    Authors: Tejal A Patel, Bhuvanesh Dave, Angel A Rodriguez, Jenny C Chang, Edith A Perez and Gerardo Colon-Otero
    Citation: Breast Cancer Research 2014 16:419

    The Erratum to this article has been published in Breast Cancer Research 2014 16:468

  3. Poly (ADP-ribose) polymerase (PARP) inhibitors and platinum-based chemotherapies have been found to be particularly effective in tumors that harbor deleterious germline or somatic mutations in the BRCA1 or BRCA2 ...

    Authors: Johnathan A Watkins, Sheeba Irshad, Anita Grigoriadis and Andrew NJ Tutt
    Citation: Breast Cancer Research 2014 16:211
  4. Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate that is effective and generally well tolerated when administered as a single agent to treat advanced breast cancer. Efficacy has now been demonstrate...

    Authors: Mark Barok, Heikki Joensuu and Jorma Isola
    Citation: Breast Cancer Research 2014 16:209
  5. Immunotherapy for the treatment of breast cancer can be categorized as either (a) specific stimulation of the immune system by active immunization, with cancer vaccines, or (b) passive immunization, such as tu...

    Authors: Carmen Criscitiello, Angela Esposito, Lucia Gelao, Luca Fumagalli, Marzia Locatelli, Ida Minchella, Laura Adamoli, Aron Goldhirsch and Giuseppe Curigliano
    Citation: Breast Cancer Research 2014 16:204
  6. The mammalian target of rapamycin (mTOR) pathway is a central pathway that regulates mRNA translation, protein synthesis, glucose metabolism, lipid synthesis and autophagy, and is involved in malignant transfo...

    Authors: Cecile Vicier, Maria Vittoria Dieci, Monica Arnedos, Suzette Delaloge, Patrice Viens and Fabrice Andre
    Citation: Breast Cancer Research 2014 16:203